{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:18:34Z","timestamp":1762899514721,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["n.a.","n.a.","n.a."],"award-info":[{"award-number":["n.a.","n.a.","n.a."]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12886-018-0731-4","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T07:18:15Z","timestamp":1519715895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context"],"prefix":"10.1186","volume":"18","author":[{"given":"Martin K.","family":"Schmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Reich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Blozik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Faes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas S.","family":"Bodmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvan","family":"Locher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Rapold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas M.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"issue":"8","key":"731_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135050","volume":"10","author":"MK Schmid","year":"2015","unstructured":"Schmid MK, Reich O, Faes L, Boehni SC, Bittner M, Howell JP, Thiel MA, Signorell A, Bachmann LM. Comparison of outcomes and costs of Ranibizumab and Aflibercept treatment in real-life. PLoS One. 2015;10(8):e0135050.","journal-title":"PLoS One"},{"key":"731_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/RMHP.S80536","volume":"8","author":"O Reich","year":"2015","unstructured":"Reich O, Bachmann LM, Faes L, Bohni SC, Bittner M, Howell JP, Thiel MA, Rapold R, Schmid MK. Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data. Risk Manag Healthc Policy. 2015;8:55\u201362.","journal-title":"Risk Manag Healthc Policy"},{"issue":"3","key":"731_CR3","first-page":"14","volume":"81","author":"General Assembly of the World Medical A","year":"2014","unstructured":"General Assembly of the World Medical A. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent. 2014;81(3):14\u20138.","journal-title":"J Am Coll Dent"},{"issue":"4","key":"731_CR4","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.ophtha.2010.12.019","volume":"118","author":"FG Holz","year":"2011","unstructured":"Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO, Weichselberger A, Staurenghi G. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology. 2011;118(4):663\u201371.","journal-title":"Ophthalmology"},{"key":"731_CR5","doi-asserted-by":"crossref","unstructured":"Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. Curr Med Res Opin. 27(7):1465\u201375.","DOI":"10.1185\/03007995.2011.585394"},{"key":"731_CR6","unstructured":"Schmid MK, Bachmann LM, Fas L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol."},{"key":"731_CR7","volume":"2","author":"SS Vedula","year":"2008","unstructured":"Vedula SS, Krzystolik MG. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2008;2:CD005139.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"731_CR8","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/bjo.2007.116616","volume":"91","author":"J Raftery","year":"2007","unstructured":"Raftery J, Clegg A, Jones J, Tan SC, Lotery A. Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol. 2007;91(9):1244\u20136.","journal-title":"Br J Ophthalmol"},{"key":"731_CR9","unstructured":"Aflibercept solution for injection for treating wet age-related macular degeneration. NICE technology appraisal guidance 294, guidanceniceorguk\/ta294 2013, ISBN 978\u20131\u20134731-0234-7."},{"key":"731_CR10","doi-asserted-by":"crossref","unstructured":"Johnston SS, Wilson K, Huang A, Smith D, Varker H, Turpcu A. Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. Adv Ther. 30(12):1111\u201327.","DOI":"10.1007\/s12325-013-0078-4"},{"issue":"4","key":"731_CR11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jfo.2016.11.012","volume":"40","author":"MV Duval","year":"2017","unstructured":"Duval MV, Rougier MB, Delyfer MN, Combillet F, Korobelnik JF. Real life visual and anatomic outcomes of aflibercept treatment for treatment-naive patients with exudative age-related macular degeneration. J Fr Ophtalmol. 2017;40(4):270\u20138.","journal-title":"J Fr Ophtalmol"},{"issue":"2","key":"731_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/aos.13233","volume":"95","author":"A Rasmussen","year":"2017","unstructured":"Rasmussen A, Sander B, Larsen M, Brandi S, Fuchs J, Hansen LH, Lund-Andersen H. Neovascular age-related macular degeneration treated with ranibizumab or aflibercept in the same large clinical setting: visual outcome and number of injections. Acta Ophthalmol. 2017;95(2):128\u201332.","journal-title":"Acta Ophthalmol"},{"key":"731_CR13","unstructured":"Committee on Quality of Health Care in America. Crossing the quality chasm: a new health system for the 21st century Institute of Medicine. 2001."},{"issue":"7040","key":"731_CR14","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","volume":"312","author":"N Black","year":"1996","unstructured":"Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996;312(7040):1215\u20138.","journal-title":"BMJ"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-018-0731-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T19:24:14Z","timestamp":1570821854000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-018-0731-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["731"],"URL":"https:\/\/doi.org\/10.1186\/s12886-018-0731-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"type":"electronic","value":"1471-2415"}],"subject":[],"published":{"date-parts":[[2018,2,27]]},"assertion":[{"value":"19 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study received Ethics approval from the Ethics Commission for North-East and Central Switzerland (EKNZ 2014\u2013110 Amendment) and adhered to the Declaration of Helsinki and the principles of good clinical practice.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Financial support for this study was provided by Novartis Pharma, Switzerland. The sponsor had no role in collection, analysis, and interpretation of data; writing of the paper; or in the decision to submit the paper for publication. Lucas Bachmann (LB), Livia Faes and Nicolas Bodmer are employees of medignition Inc. EB, RR and OR are employees of the Helsana Health Insurance Company, and Maximilian Kuhn is an employee of CSS Group. These funders provided support in the form of salaries but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"64"}}